Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview

Arcturus Therapeutics Holdings

04/08/2026 22:32

Arcturus Therapeutics Holdings Inc ARCT.OQ ARCT.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The San Diego California-based  company is expected to report a 88.7% decrease in revenue to $3.199 million from $28.3 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Arcturus Therapeutics Holdings Inc is for a loss of 100 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $20.00, about 233.3% above its last closing price of $6.00
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.08
-1.09
-0.95
Beat
12.7
Dec. 31 2026
-0.65
-0.71
-1.03
Missed
-44.4
Sep. 30 2025
-0.77
-0.82
-0.49
Beat
40.5​
Jun. 30 2025
-0.78
-0.89
-0.34
Beat
61.9
​​Mar. 31 2025
-1.26
-1.33
-0.52
Beat
60.9
Dec. 31 2024
-0.52
-0.55
-1.11
Missed
-102.2​
Sep. 30 2024
-1.23
-1.22
-0.26
Beat
78.6
Jun. 30 2024
-1.51
-1.60
-0.64
Beat
60
This summary was machine generated August 4 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)